Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 9 |
| 1.1 List of Tables | 6 | 4 |
| 1.2 List of Figures | 10 | 1 |
| 2 Introduction | 11 | 1 |
| 2.1 Leukemia Diagnostic Tests Overview | 11 | 1 |
| 3 Products under Development | 12 | 4 |
| 3.1 Leukemia Diagnostic Tests - Pipeline Products by Stage of Development | 12 | 1 |
| 3.2 Leukemia Diagnostic Tests - Pipeline Products by Territory | 13 | 1 |
| 3.3 Leukemia Diagnostic Tests - Pipeline Products by Regulatory Path | 14 | 1 |
| 3.4 Leukemia Diagnostic Tests - Pipeline Products by Estimated Approval Date | 15 | 1 |
| 4 Leukemia Diagnostic Tests - Pipeline Products under Development by Companies | 16 | 5 |
| 4.1 Leukemia Diagnostic Tests Companies - Pipeline Products by Stage of Development | 16 | 2 |
| 4.2 Leukemia Diagnostic Tests - Pipeline Products by Stage of Development | 18 | 3 |
| 5 Leukemia Diagnostic Tests Companies and Product Overview | 21 | 66 |
| 5.1 Abbott Diagnostics Company Overview | 21 | 1 |
| 5.1.1 Abbott Diagnostics Pipeline Products &Ongoing Clinical Trials Overview | 21 | 3 |
| 5.2 Acobiom Company Overview | 24 | 1 |
| 5.2.1 Acobiom Pipeline Products &Ongoing Clinical Trials Overview | 24 | 1 |
| 5.3 Adaptive Biotechnologies Corp Company Overview | 25 | 1 |
| 5.3.1 Adaptive Biotechnologies Corp Pipeline Products &Ongoing Clinical Trials Overview | 25 | 1 |
| 5.4 Aegis Sciences Corporation Company Overview | 26 | 1 |
| 5.4.1 Aegis Sciences Corporation Pipeline Products &Ongoing Clinical Trials Overview | 26 | 1 |
| 5.5 BioSense Technologies, Inc. Company Overview | 27 | 1 |
| 5.5.1 BioSense Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 27 | 1 |
| 5.6 Cancer Genetics Inc Company Overview | 28 | 1 |
| 5.6.1 Cancer Genetics Inc Pipeline Products &Ongoing Clinical Trials Overview | 28 | 2 |
| 5.7 CeMines, Inc. Company Overview | 30 | 1 |
| 5.7.1 CeMines, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 30 | 1 |
| 5.8 Cepheid Company Overview | 31 | 1 |
| 5.8.1 Cepheid Pipeline Products &Ongoing Clinical Trials Overview | 31 | 2 |
| 5.9 Di.V.A.L Toscana srl Company Overview | 33 | 1 |
| 5.9.1 Di.V.A.L Toscana srl Pipeline Products &Ongoing Clinical Trials Overview | 33 | 1 |
| 5.10 DiaSorin S.p.A Company Overview | 34 | 1 |
| 5.10.1 DiaSorin S.p.A Pipeline Products &Ongoing Clinical Trials Overview | 34 | 6 |
| 5.11 Eutropics Pharmaceuticals Inc Company Overview | 40 | 1 |
| 5.11.1 Eutropics Pharmaceuticals Inc Pipeline Products &Ongoing Clinical Trials Overview | 40 | 4 |
| 5.12 H. Lee Moffitt Cancer Center &Research Institute Inc Company Overview | 44 | 1 |
| 5.12.1 H. Lee Moffitt Cancer Center &Research Institute Inc Pipeline Products &Ongoing Clinical Trials Overview | 44 | 1 |
| 5.13 Health Discovery Corp Company Overview | 45 | 1 |
| 5.13.1 Health Discovery Corp Pipeline Products &Ongoing Clinical Trials Overview | 45 | 2 |
| 5.14 InVivoScribe Technologies Inc Company Overview | 47 | 1 |
| 5.14.1 InVivoScribe Technologies Inc Pipeline Products &Ongoing Clinical Trials Overview | 47 | 2 |
| 5.15 IV Diagnostics, Inc. Company Overview | 49 | 1 |
| 5.15.1 IV Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 49 | 1 |
| 5.16 Jaden BioScience Inc. Company Overview | 50 | 1 |
| 5.16.1 Jaden BioScience Inc. Pipeline Products &Ongoing Clinical Trials Overview | 50 | 1 |
| 5.17 King's College London Company Overview | 51 | 1 |
| 5.17.1 King's College London Pipeline Products &Ongoing Clinical Trials Overview | 51 | 1 |
| 5.18 Monoquant Pty. Ltd. Company Overview | 52 | 1 |
| 5.18.1 Monoquant Pty. Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 52 | 1 |
| 5.19 Nodality Inc Company Overview | 53 | 1 |
| 5.19.1 Nodality Inc Pipeline Products &Ongoing Clinical Trials Overview | 53 | 1 |
| 5.20 NuCana BioMed Ltd Company Overview | 54 | 1 |
| 5.20.1 NuCana BioMed Ltd Pipeline Products &Ongoing Clinical Trials Overview | 54 | 6 |
| 5.21 Nuclea Biotechnologies Inc. (Inactive) Company Overview | 60 | 1 |
| 5.21.1 Nuclea Biotechnologies Inc. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview | 60 | 2 |
| 5.22 OncoVista Innovative Therapies Inc Company Overview | 62 | 1 |
| 5.22.1 OncoVista Innovative Therapies Inc Pipeline Products &Ongoing Clinical Trials Overview | 62 | 2 |
| 5.23 Qiagen NV Company Overview | 64 | 1 |
| 5.23.1 Qiagen NV Pipeline Products &Ongoing Clinical Trials Overview | 64 | 2 |
| 5.24 Roche Diagnostics International Ltd Company Overview | 66 | 1 |
| 5.24.1 Roche Diagnostics International Ltd Pipeline Products &Ongoing Clinical Trials Overview | 66 | 2 |
| 5.25 Siemens Healthcare GmbH Company Overview | 68 | 1 |
| 5.25.1 Siemens Healthcare GmbH Pipeline Products &Ongoing Clinical Trials Overview | 68 | 1 |
| 5.26 SkylineDx BV Company Overview | 69 | 1 |
| 5.26.1 SkylineDx BV Pipeline Products &Ongoing Clinical Trials Overview | 69 | 2 |
| 5.27 St. Jude Children s Research Hospital Inc Company Overview | 71 | 1 |
| 5.27.1 St. Jude Children s Research Hospital Inc Pipeline Products &Ongoing Clinical Trials Overview | 71 | 2 |
| 5.28 Stanford University Company Overview | 73 | 1 |
| 5.28.1 Stanford University Pipeline Products &Ongoing Clinical Trials Overview | 73 | 1 |
| 5.29 The Feinstein Institute for Medical Research Company Overview | 74 | 1 |
| 5.29.1 The Feinstein Institute for Medical Research Pipeline Products &Ongoing Clinical Trials Overview | 74 | 2 |
| 5.30 University of Barcelona Company Overview | 76 | 1 |
| 5.30.1 University of Barcelona Pipeline Products &Ongoing Clinical Trials Overview | 76 | 1 |
| 5.31 University of California San Diego Company Overview | 77 | 1 |
| 5.31.1 University of California San Diego Pipeline Products &Ongoing Clinical Trials Overview | 77 | 2 |
| 5.32 University of Colorado Company Overview | 79 | 1 |
| 5.32.1 University of Colorado Pipeline Products &Ongoing Clinical Trials Overview | 79 | 1 |
| 5.33 University of Missouri Company Overview | 80 | 1 |
| 5.33.1 University of Missouri Pipeline Products &Ongoing Clinical Trials Overview | 80 | 1 |
| 5.34 Vela Diagnostics Pte. Ltd Company Overview | 81 | 1 |
| 5.34.1 Vela Diagnostics Pte. Ltd Pipeline Products &Ongoing Clinical Trials Overview | 81 | 1 |
| 5.35 Vivia Biotech SL Company Overview | 82 | 1 |
| 5.35.1 Vivia Biotech SL Pipeline Products &Ongoing Clinical Trials Overview | 82 | 2 |
| 5.36 Wake Forest Baptist Medical Center Company Overview | 84 | 1 |
| 5.36.1 Wake Forest Baptist Medical Center Pipeline Products &Ongoing Clinical Trials Overview | 84 | 1 |
| 5.37 Xiamen Zeesan Biotech Co.,Ltd Company Overview | 85 | 1 |
| 5.37.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products &Ongoing Clinical Trials Overview | 85 | 2 |
| 6 Leukemia Diagnostic Tests - Recent Developments | 87 | 67 |
| 6.1 Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability | 87 | 1 |
| 6.2 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance | 88 | 2 |
| 6.3 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 | 90 | 3 |
| 6.4 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results | 93 | 4 |
| 6.5 Nov 01, 2016: Asuragen Launches QuantideX NGS RNA Lung Cancer Kit | 97 | 1 |
| 6.6 Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance | 98 | 2 |
| 6.7 Oct 26, 2016: NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 | 100 | 2 |
| 6.8 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters | 102 | 6 |
| 6.9 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation | 108 | 1 |
| 6.10 Sep 20, 2016: LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development | 109 | 1 |
| 6.11 Sep 13, 2016: Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 | 110 | 1 |
| 6.12 Sep 13, 2016: Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 | 110 | 1 |
| 6.13 Sep 09, 2016: Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants | 110 | 1 |
| 6.14 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research | 110 | 1 |
| 6.15 Sep 02, 2016: Danaher Acquires Cepheid | 111 | 1 |
| 6.16 Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates | 112 | 1 |
| 6.17 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter | 113 | 1 |
| 6.18 Aug 04, 2016: Diasorin Group Revenues And EBITDA Reached Record highs In the Second Quarter 2016 | 114 | 4 |
| 6.19 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results | 118 | 4 |
| 6.20 Aug 02, 2016: Kyowa Hakko Kirin Completed of Construction for the Biopharmaceutical API Manufacturing Facility in the Takasaki Plant | 122 | 1 |
| 6.21 Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017 | 123 | 3 |
| 6.22 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors | 126 | 1 |
| 6.23 Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results | 126 | 1 |
| 6.24 Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance | 127 | 2 |
| 6.25 Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 | 129 | 1 |
| 6.26 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects | 130 | 6 |
| 6.27 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia | 136 | 1 |
| 6.28 Jul 05, 2016: MolecularMD Raises USD0.5 Million in Venture Financing | 137 | 1 |
| 6.29 Jul 05, 2016: Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture | 137 | 1 |
| 6.30 Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board | 138 | 1 |
| 6.31 Jun 30, 2016: Wake Forest Baptist Receives Specialty Pharmacy Accreditation | 138 | 1 |
| 6.32 Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance | 138 | 1 |
| 6.33 Jun 21, 2016: Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays | 139 | 1 |
| 6.34 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts | 139 | 1 |
| 6.35 Jun 15, 2016: Siemens Healthcare Becomes Siemens Healthineers | 140 | 1 |
| 6.36 Jun 09, 2016: Liquid biopsy test - GATCLIQUID ONCOTARGET - expanded to cover blood cancers such as acute myeloid leukaemia | 140 | 1 |
| 6.37 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 | 141 | 1 |
| 6.38 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 | 141 | 1 |
| 6.39 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 | 142 | 1 |
| 6.40 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 | 142 | 1 |
| 6.41 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 | 143 | 1 |
| 6.42 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event | 143 | 2 |
| 6.43 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors | 145 | 1 |
| 6.44 May 18, 2016: Wake Forest Baptist Fiscal Year 2016 Third Quarter Financial Performance | 145 | 1 |
| 6.45 May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis | 146 | 1 |
| 6.46 May 17, 2016: ArcherDX Launches NGS Assays for Hematological Malignancy Profiling | 147 | 1 |
| 6.47 May 13, 2016: Wake Forest Baptist Reports Record $376.3 Million in Community Benefits during 2015 Fiscal Year | 147 | 1 |
| 6.48 May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights | 148 | 1 |
| 6.49 Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For $784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program | 149 | 1 |
| 6.50 Mar 29, 2016: German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position | 150 | 1 |
| 6.51 Mar 04, 2016: Wake Forest Baptist Announces Starbuck Promoted to Vice President Position | 151 | 1 |
| 6.52 Mar 04, 2016: Wake Forest Baptist Announces Lord Promoted to Vice President Position | 151 | 1 |
| 6.53 Mar 04, 2016: Wake Forest Baptist Names New Chair of Emergency Medicine | 152 | 1 |
| 6.54 Mar 01, 2016: Study confirms early MRI screening reduces Risk of Breast cancer Death for survivors of Childhood Hodgkin's lymphoma | 152 | 1 |
| 6.55 Feb 29, 2016: Wake Forest Baptist Fiscal Year 2016 Second Quarter Financial Performance | 153 | 1 |
| 7 Appendix | 154 | 4 |
| 7.1 Methodology | 154 | 3 |
| 7.2 About GlobalData | 157 | 1 |
| 7.3 Contact Us | 157 | 1 |
| 7.4 Disclaimer | 157 | 1 |
